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OBJECTIVE: The study purpose was to determine the re-
lationship between pain severity and sumatriptan and
OTC medication use for migraine attack treatment.
METHODS: This study was part of a larger 6-month,
prospective, observational study evaluating migraine-
related outcomes in migraineurs within a managed care
organization (MCO). The MCO is a mixed staff and in-
dependent practice association model. Enrolled patients
were those who received their first prescription for
sumatriptan and had been a member of the MCO for at
least 6 months. Pain severity was self-recorded by pa-
tients as mild, moderate, or severe when each dose of
medication was taken during the attack.
RESULTS: A total of 168 patients reported 1,304 mi-
graine attacks with an average of 1.3 attacks/member!
month. Of the 1,304 attacks, 32% were mild, 43% were
moderate, and 25% were severe at the time the first mi-
graine medication was taken. Sumatriptan was used in
82% of migraine attacks. Patients were more likely to use
sumatriptan during severe migraine attacks (86%) than
in mild attacks (79%) (p < 0.05). Patients were more
likely to use OTC medications during mild attacks (55%)
than in severe attacks (20%) (p < 0.05). Patients who
took sumatriptan as the first medication during an attack
took fewer medication doses (2.4) than in attacks where
sumatriptan was used as a second or subsequent dose
(4.7) (p < 0.05).
CONCLUSION: This observational study shows that mi-
graineurs in managed care tend to use OTC medications
for mild migraine attacks and sumatriptan for severe at-
tacks. Additional studies should be performed to evaluate
the clinical and cost outcomes of this effect and to develop
migraine medication treatment protocols to encourage ap-
propriate treatment and management of migraine.
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Previous studies of antidepressants in clinical practice
have established a link between initial antidepressant se-
lection and patterns of antidepressant use and health care
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expenditures. However, there has been far less research
to date demonstrating a link between the patterns of anti-
depressant use and patients' clinical outcomes using data
from actual clinical practice.
OBJECTIVE: The purpose of this study using data from
a clinical practice setting was to test whether the pattern
of antidepressant use was correlated with patients' treat-
ment response as measured by the score on the Clinical
Global Impressions-Improvement scale.
DATA AND METHODS: A dataset of patients who initi-
ated therapy on one the most common selective serotonin
reuptake inhibitors (SSRIs) fluoxetine, fluvoxamine, par-
oxetine, or sertraline in a general practitioner setting in
Spain was used. A Cox proportional hazard analysis was
used to predict the likelihood of treatment response based
upon the pattern of initial antidepressant use, while con-
trolling for the influence of other baseline characteristics.
RESULTS: After controlling for other observed baseline
characteristics including initial disease severity, patients
who remained on their initial antidepressant therapy for
at least two months with no switching, augmentation, or
upward dose titration were 63.2% more likely (p < 0.05)
than patients who had an adjustment to therapy to expe-
rience a treatment response.
CONCLUSION: The pattern of antidepressant use is an
important determinant of treatment response among pa-
tients initiating therapy on the newer antidepressants in
clinical practice.
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Study of the duration and pattern of antidepressant use in
the naturalistic setting can provide important insights
into how antidepressant use patterns compare to recom-
mended depression treatment guidelines. The World
Health Organization and consensus groups in the United
Kingdom have, for example, established depression treat-
ment guidelines recommending at least four to nine
months of antidepressant therapy beyond initial symp-
tom resolution for depressive episodes. In light of the in-
creased use of selective serotonin reuptake inhibitors
(SSRIs), it is reasonable to evaluate whether differences
exist among individual SSRIs in their use relative to
guidelines.
OBJECTIVE: The purpose of this study was to assess the
effects of initial SSRI antidepressant selection on the sub-
sequent pattern and duration of antidepressant use across
drug types in actual clinical practice in the United States,
among patients who had an indicator of a depression-
related diagnosis on their insurance claims forms and
were given an initial drug selection.
METHODS AND DATA: Logistic regression analysis of
